Clinical trials: Cardiovascular Disease
Arrhythmogenic Cardiomyopathy, PKP2-ACM
A Study to Assess Real-world Patient Characteristics and Clinical Course for Symptomatic Patients With PKP2-ACM
An observational study to assess real-world patient characteristics and clinical course of disease in participants with PKP2-ACM.
- Conditions
- Arrhythmogenic Cardiomyopathy, PKP2-ACM, PKP2-ARVC
- Trial name
- SNAPSHOT- PKP2 (NCT06976606)
- Where
- 6 sites in United States
- Volunteers
- 40 people
- Sponsor
- Lexeo Therapeutics
Heart Failure, Crackles
Heart Failure Monitoring With Eko Electronic Stethoscopes
This proof-of-concept study will evaluate the feasibility of the Eko DUO to measure signals relevant to heart failure (HF) decompensation, as well as the feasibility to develop an algorithm to model hemodynamic filling pressures…
- Conditions
- Heart Failure, Crackles, Heart Failure With Preserved Ejection Fraction
- Trial name
- HOME0 (NCT04404452)
- Testing
- Use of Eko CORE and Eko DUO electronic stethoscopes
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Eko Devices, Inc.
Multiple Myeloma, Relapsed/Refractory Multiple Myeloma
A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma
This is a Phase 2, open-label, single-arm, multicenter study to assess the antimyeloma activity and further characterize the safety, tolerability, PK, and PD of cemsidomide in combination with dexamethasone in participants with…
- Trial name
- MOMENTUM (NCT07284758)
- Testing
- Cemsidomide, Dexamethasone
- Where
- 60 sites in United States, France and 4 more
- Volunteers
- 100 people
- Sponsor
- C4 Therapeutics, Inc.
Patent Foramen Ovale, PFO
Lifetech Cera™ PFO Occluder Post-Market Clinical Follow-Up
The objective of this post-market registry is to assess the clinical use of the Lifetech Cera™ PFO Occluder in a real-world and on-label fashion.
- Trial name
- NCT05893758
- Testing
- The Cera™ PFO Occluder
- Where
- 5 sites in Poland
- Volunteers
- 94 people
- Sponsor
- Lifetech Scientific (Shenzhen) Co., Ltd.
Multiple Myeloma and Plasma Cell Neoplasm
Bortezomib, Ascorbic Acid, and Melphalan in Treating Patients With Newly Diagnosed Multiple Myeloma
RATIONALE: Bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as melphalan, work in different ways to stop the growth of cancer cells, either by…
- Trial name
- NCT00317811
- Testing
- ascorbic acid, bortezomib, melphalan
- Where
- 8 sites in United States
- Volunteers
- 35 people
- Sponsor
- Oncotherapeutics
Heart Failure
Early Feasibility Study of the Edwards APTURE Transcatheter Shunt System
The objectives of this early feasibility study are to: evaluate initial clinical safety, device functionality, and effectiveness of the APTURE system for treatment of symptomatic HFrEF patients with elevated LAP, provide guidance…
- Trial name
- ALT-FLOW HFrEF (NCT07858799)
- Testing
- Edwards APTURE transcatheter shunt system
- Where
- 3 sites in Germany
- Volunteers
- 15 people
- Sponsor
- Edwards Lifesciences
Tumors, Lymphoma
Safety Study of Ridaforolimus in Patients With Advanced, Refractory or Recurrent Malignancies (MK-8669-001 AM5)(COMPLETED)
Phase 1 trial to determine the safety, tolerability and maximum tolerated dose (MTD) of ridaforolimus in patients with refractory or recurrent malignancies, including myeloma and lymphoma.
- Conditions
- Tumors, Lymphoma, Multiple Myeloma
- Trial name
- NCT00060632
- Testing
- ridaforolimus
- Volunteers
- 46 people
- Sponsor
- Merck Sharp & Dohme LLC
Vascular Closure, Endovascular Procedure
Post-Market Clinical Investigation of the FemoSeal™ VCS: A Prospective, Multi-Center Observational European Study
The study aims to further demonstrate the safety and effectiveness of the FemoSeal™ VCS in achieving hemostasis following percutaneous endovascular procedures performed via the common femoral artery (CFA) access site.
- Conditions
- Vascular Closure, Endovascular Procedure, Hemostasis, Peripheral Vascular Disease
- Trial name
- FEMOSEAL CLOSE (NCT05027698)
- Where
- 3 sites in Belgium, France and 1 more
- Volunteers
- 230 people
- Sponsor
- Terumo Europe N.V.
Myocardial Infarction
Firibastat or Ramipril After Acute Myocardial Infarction for Prevention of Left Ventricular Dysfunction
This is a multicenter, randomized, double-blind, active-controlled, dose-titrating phase 2 study to evaluate the safety and efficacy of firibastat administered orally BID (2 daily doses) versus ramipril administered orally BID…
- Trial name
- QUORUM (NCT03715998)
- Testing
- Ramipril, Firibastat
- Where
- 7 sites in France, Germany and 5 more
- Volunteers
- 295 people
- Sponsor
- Quantum Genomics SA
Coronary Chronic Total Occlusions, Ischemic Heart Disease
Acolyte CTO-PCI Study: Imaging and Catheter System to Treat Patients With Coronary Chronic Total Occlusion, Who Have Persistent Symptoms Following Medical Therapy and Are Undergoing Percutaneous Coronary Interventional Procedures
This is a study to evaluate the safety and effectiveness of the Acolyte Catheter System used in CTO-PCI procedures. The system will be used for the placement and positioning of guidewires and catheters in the coronary vasculature…
- Conditions
- Coronary Chronic Total Occlusions, Ischemic Heart Disease, Ischemic Heart Disease (IHD), Ischemic Heart Disease Chronic
- Trial name
- NCT06795763
- Testing
- CTO-PCI Procedure with Acolyte Catheter System
- Where
- 5 sites in United States
- Volunteers
- 115 people
- Sponsor
- Elumn8 Medical
Tricuspid Valve Insufficiency
EASE TRICUSPID Expertise-based Assessment Study on Clinical Efficacy of Contour 3D® in TRICUSPID Valve Annuloplasty
Few clinical evidence for the Contour 3D Tricuspid Annuloplasty Ring exists; therefore, in order to position this product on the market, a post-market release study was completed.
- Trial name
- NCT01532921
- Testing
- Tricuspid valve repair, Left-sided heart surgery, Contour 3D Tricuspid Annuloplasty Ring
- Where
- 7 sites in France, Germany and 1 more
- Volunteers
- 85 people
- Sponsor
- Medtronic Cardiac Rhythm and Heart Failure
Atrial Fibrillation
High Intensity Focused Ultrasound (HIFU) Ablation System Study
The purpose of this study is to determine if the HIFU Pulmonary Vein Ablation System is effective in the treatment of paroxysmal Atrial Fibrillation compared to the control of best medical therapy with FDA approved antiarrhythmic…
- Trial name
- NCT00392106
- Testing
- propafenone, flecainide, dofetilide
- Where
- 21 sites in United States, Czechia
- Volunteers
- 240 people
- Sponsor
- ProRhythm, Inc.
Multiple Myeloma
A Safety Study of SEA-BCMA in Patients With Multiple Myeloma
This trial will study SEA-BCMA to find out whether it is an effective treatment for multiple myeloma (MM) and what side effects (unwanted effects) may occur. The study will have several parts.
- Trial name
- NCT03582033
- Testing
- SEA-BCMA, dexamethasone, pomalidomide
- Where
- 13 sites in United States
- Volunteers
- 83 people
- Sponsor
- Seagen Inc.
Waldenstrom's Macroglobulinemia
A Study of Mavorixafor in Combination With Ibrutinib in Participants With Waldenstrom's Macroglobulinemia (WM) Whose Tumors Express Mutations in MYD88 and CXCR4
The primary objective of the study is to establish a pharmacologically active dose of mavorixafor in combination with ibrutinib based on pooled safety, clinical response, pharmacokinetic (PK) and pharmacodynamic (PD) data to…
- Trial name
- NCT04274738
- Testing
- Mavorixafor, Ibrutinib
- Where
- 5 sites in United States, Greece
- Volunteers
- 16 people
- Sponsor
- X4 Pharmaceuticals
Multiple Myeloma in Relapse, Refractory Multiple Myeloma
TJ202 Combined With Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma
This trial is a multi-center, single-arm phase 2 study to evaluate the efficacy and safety of TJ202 combined with dexamethasone in subjects with relapsed or refractory multiple myeloma (RRMM) who received at least 2 prior lines…
- Trial name
- NCT03860038
- Testing
- TJ202 and Dexamethasone
- Where
- 18 sites in China, Taiwan
- Volunteers
- 113 people
- Sponsor
- TJ Biopharma Co., Ltd.
Peripheral Arterial Disease (PAD)
Zilver® Flex™ Vascular Stent Study
This study is intended to evaluate the long-term effectiveness of treatment of de novo or restenotic lesions of the above-the-knee femoropopliteal artery using the Zilver® Flex™ Vascular Stent which has received the CE mark for…
- Trial name
- NCT00827619
- Testing
- Zilver® Flex™ Vascular Stent
- Where
- 3 sites in Germany
- Volunteers
- 110 people
- Sponsor
- Cook Group Incorporated
Aortic Stenosis
ACURATE Neo™ TA Delivery System in Patient With Severe Aortic Stenosis
The purpose of this investigation is to collect data pertaining to the safety and performance of the ACURATE neo (TM) Aortic Bioprosthesis as implanted with the ACURATE neo (TM) TA Transapical Delivery System.
- Trial name
- NCT02950428
- Testing
- ACURATE neo™TA Delivery System
- Where
- 7 sites in Germany
- Volunteers
- 60 people
- Sponsor
- Symetis SA
Coronary Artery Disease
Efficacy of Automated Distal Vascular Anastomosis in Coronary Surgery: Phase II
This evaluation is designed to evaluate the feasibility of using an automated distal coronary anastomotic to facilitate grafting of the left internal mammary artery to the left anterio descending coronary artery during myocardial…
- Trial name
- NCT00292500
- Testing
- Automated distal anastomotic device
- Where
- Germany
- Volunteers
- 170 people
- Sponsor
- Cardica, Inc
Solid Cancers, NSCLC (Advanced Non-small Cell Lung Cancer)
An Phase Ib/II Clinical Trial of TCC1727 Combination Therapy in Advanced Solid Tumors
This is a Phase Ib/II clinical study. The Phase Ib dose-escalation study aims to evaluate and determine the recommended Phase II dose (RP2D) of TCC1727 in combination with benmelstobart /olaparib /topotecanfor patients with…
- Conditions
- Solid Cancers, NSCLC (Advanced Non-small Cell Lung Cancer), Gastric (Stomach) Cancer, Endometrial Cancer
- Trial name
- NCT07371663
- Testing
- TCC1727 tablet 90mg, TCC1727 tablet 120mg, TCC1727 tablet 160mg
- Where
- 3 sites in China
- Volunteers
- 266 people
- Sponsor
- Beijing Tide Pharmaceutical Co., Ltd
Hypertension
CKD-828(80/2.5mg) Pharmacokinetic Study
The purpose of this study is to evaluate the pharmacokinetic characteristics of CKD-828(Fixed Dose Combination Tablet; Telmisartan and S-Amlodipine) in healthy volunteer.
- Trial name
- NCT01246193
- Testing
- CKD-828(FDC), Combination Therapy
- Where
- South Korea
- Volunteers
- 65 people, healthy volunteers welcome
- Sponsor
- Chong Kun Dang Pharmaceutical